Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, 4D Molecular Therapeutics, Inc. reported revenue of $85M, up 230194.6% year over year. Operating margin was -187.2% and net margin -164.4%, on a free-cash-flow margin of -128.6% with capital expenditure at 0.6% of revenue. Every figure is computed directly from FDMT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $85M | -187.2% | -164.4% |
| FY2024 | $0M | -507678.4% | -434778.4% |
| FY2023 | $21M | -544.6% | -486.6% |
| FY2022 | $3M | -3516.5% | -3435.4% |
| FY2021 | $18M | -395.5% | -395.4% |
How does FDMT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.